BMS2047_06 Other Considerations Lecture Notes PDF

Other considerations Lecture Bite 4 Student feedback and consultation Thursday 27/04/23 13.00 – 14.00 Friday 05/05/23 13.00 – 14.00 Click here for other weeks Other factors affecting our choice  Genetics: BRCA1 or BRCA2 mutation  Combination therapy approach  THINGS TO CONSIDER:  Drug : Drug int...

Other considerations Lecture Bite 4 Student feedback and consultation Thursday 27/04/23 13.00 – 14.00 Friday 05/05/23 13.00 – 14.00 Click here for other weeks Other factors affecting our choice  Genetics: BRCA1 or BRCA2 mutation  Combination therapy approach  THINGS TO CONSIDER:  Drug : Drug interactions  Resistance to these treatments  Tolerance of side effects  £££ Foster et al (2011) Cancer Treatment Reviews 37: 405-415 Side Effects & Resistance Holohan (2013) Nature Reviews in Cancer Survival of treatment resistant cells Khan et al., (2015) Asian Pac J Cancer Prev. 16(16):6831-6839 To post on the discussion board click here References GENERAL: Rang & Dales Pharmacology (2016) 8th Edition, Elsevier. IN MORE DETAIL: Or come and talk to me  Starobova, H., and Vetter, I. (2017) Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Frontiers in Molecular Neuroscience 10(174):1-21  Kolch, W & Pitt, A. (2010) Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer 10(9):618-29  Patel, H.K., & Bihani, T. (2018) Selective Eoestrogen Recptor Modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacology & Therapeutics 186:1–24  Foster, T., et al. (2011) The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treatment Reviews 37: 405-415  Barthelemy, P., LeBlanc, J., Goldbarg, V., Wendling, F., & Kurtz, J-E. (2014) ANTICANCER RESEARCH 34: 14831492  Barbier, P., Tsvetkov, P.O., Breuzard, G., & Devred, F. (2014) Deciphering the molecular mechanisms of antitubulin plant derived drugs. Phytochemistry Reviews 13(1): 157–169  Weaver, B.A. (2014) How Taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell 25: 2677-81  Khan et al., (2015) Enhancing Activity of Anticancer Drugs in Multidrug Resistant Tumors by Modulating PGlycoprotein through Dietary Nutraceuticals. Asian Pac J Cancer Prev. 16(16):6831-6839  Holohan, C., Van Schaeybroeck, S., Longley, D.B., & Johnston, P.G. (2013) Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer 13: 714–726  Agneyo Ganguly et al. (2007) Betulinic Acid, a Catalytic Inhibitor of Topoisomerase I, Inhibits Reactive Oxygen Species–Mediated Apoptotic Topoisomerase I–DNA Cleavable Complex Formation in Prostate Cancer Cells but Does Not Affect the Process of Cell Death. Cancer Res 67:11848-11858  Pommier, Y. (2009) DNA Topoisomerase I Inhibitors: Chemistry, Biology and Interfacial Inhibition. Chem Rev. 109(7): 2894–2902.